CN100393303C - Vitamin A liposome artificial lacrimal eye drops - Google Patents
Vitamin A liposome artificial lacrimal eye drops Download PDFInfo
- Publication number
- CN100393303C CN100393303C CNB2006100838419A CN200610083841A CN100393303C CN 100393303 C CN100393303 C CN 100393303C CN B2006100838419 A CNB2006100838419 A CN B2006100838419A CN 200610083841 A CN200610083841 A CN 200610083841A CN 100393303 C CN100393303 C CN 100393303C
- Authority
- CN
- China
- Prior art keywords
- vitamin
- liposome
- chloride
- fat
- palmitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 36
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 title claims abstract description 33
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 title claims abstract description 31
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 title claims abstract description 29
- 235000019155 vitamin A Nutrition 0.000 title claims abstract description 29
- 239000011719 vitamin A Substances 0.000 title claims abstract description 29
- 229940045997 vitamin a Drugs 0.000 title claims abstract description 28
- 239000003889 eye drop Substances 0.000 title claims abstract description 23
- 229940012356 eye drops Drugs 0.000 title claims description 9
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims abstract description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 48
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 44
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 35
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 34
- 239000000607 artificial tear Substances 0.000 claims abstract description 33
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 24
- 229940108325 retinyl palmitate Drugs 0.000 claims abstract description 24
- 235000019172 retinyl palmitate Nutrition 0.000 claims abstract description 24
- 239000011769 retinyl palmitate Substances 0.000 claims abstract description 24
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 22
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960000342 retinol acetate Drugs 0.000 claims abstract description 22
- 235000019173 retinyl acetate Nutrition 0.000 claims abstract description 22
- 239000011770 retinyl acetate Substances 0.000 claims abstract description 22
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims abstract description 22
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 22
- 239000011709 vitamin E Substances 0.000 claims abstract description 22
- 229940046009 vitamin E Drugs 0.000 claims abstract description 22
- 208000005494 xerophthalmia Diseases 0.000 claims abstract description 20
- 239000001103 potassium chloride Substances 0.000 claims abstract description 17
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 16
- 239000001110 calcium chloride Substances 0.000 claims abstract description 16
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910001868 water Inorganic materials 0.000 claims abstract description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 8
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000012530 fluid Substances 0.000 claims description 21
- 230000000887 hydrating effect Effects 0.000 claims description 21
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 17
- 239000008347 soybean phospholipid Substances 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 15
- 235000002639 sodium chloride Nutrition 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 13
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 208000003464 asthenopia Diseases 0.000 abstract description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 229940041616 menthol Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000000823 artificial membrane Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000036040 emmetropia Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- -1 salt cetrimonium bromide Chemical class 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a vitamin A liposome artificial lacrimal eye drop which is used for controlling xerophthalmia and eyestrain. The present invention is composed of fat-soluble vitamin A, liposome encapsulating material, vitamin E, and artificial tear hydrated liquor, wherein the fat-soluble vitamin A is vitamin A palmitate or vitamin A acetate; the liposome encapsulating material is granulesten and cholesterol; the components of the artificial tear hydrated liquor are sodium bicarbonate, sodium chloride, dextrose, potassium chloride, calcium chloride, water, etc., and in addition, one or a plurality of the auxiliary components of menthol, PVP, HPMC, etc. can also be added in the artificial tear hydrated liquor.
Description
Technical field:
The present invention relates to a kind of eye drop, particularly contain the liposome artificial lacrimal eye drops of vitamin A.Be used to prevent and treat xerophthalmia and eyestrain.
Background technology:
The generation reason of xerophthalmia or title drying property conjunctiva, xerophthalmia mainly contains the following aspects:
1. owing to advanced age, do not have enough sleep, physiological reasons such as psychentonia cause the tear downgrade.
2. take the influence that part depressor and part psychosis produce tear, some contraceptive can reduce the generation of tear at present.
4. be engaged in computer operation, car steering, reading and other fine manipulation for a long time.
5. owing to other reasons such as contact lens, anaphylaxis conjunctivitis, atmospheric pollution, ultraviolet, and the oligodacrya that causes, downgrade.
6. the xerophthalmia patient has in the environment of wind the air-flow sensitivity, makes bitot's patches especially easily, therefore, indoor than outdoor much comfortable; The xerophthalmia scheorma sense was serious when night or early morning woke up, because the generation of tear reduces during sleep.
Wherein, the main cause of trouble xerophthalmia is that the number of times minimizing causes because eyes blink.According to statistics, people's emmetropia number of times that blinks is per minute 15 times, and it only is 4 ~ 5 times during computation, be 2 ~ 3 times when driving, as the number of times that blinks reduces 75%, will be because of lacrimal secretion obviously reduce, the aerial time of corneal exposure surpasses breakup time of tear film, can't form complete tear film and suffers from xerophthalmia.
The main pathogeny of xerophthalmia is exactly because the conjunctiva that the deficiency of the matter of tear film or amount causes before the cornea, the result that corneal epithelium can not be kept normal function.The tear film is by as thin as a wafer surperficial fat layer (10.5 μ m) and be rich in proteinpolysaccharide and mucinous water layer is formed, the fat layer has the effect that delays the evaporation of tear film, and under 30% relative humidity condition, tear film evaporation rate is 3ml/h, evaporation reduces during high humidity, and evaporation increases when dry.
The local application of xerophthalmia mainly is the artificial tears.Five stages have been experienced in artificial tears's development, are the of short duration normal saline of effect etc. in early days; Be methylcellulose (methylcellulose) (prolong action time, but make blurred vision) in 1945 then; It is later on polyvinyl alcohol (polyvinylalcohol, PVA tool film forming character) in 1964; Then be artificial tears such as the TearsNatural (tear is right) that contains the polymer of eye table tool characterization of adsorption, and SR-AT (slow release artificial tear, slow-release artificial tears); Present artificial tears uses polyacrylic acid (polyacrylic acid, effectiveness and toleration all are better than PVA) etc., adds various nutrients or medicine to make, and is intended to make the artificial tears to be turned to by simple moistening eye table and promotes a surface drying change rehabilitation simultaneously.
From the experiment and the clinical research of xerophthalmia traditional Chinese medical science topical therapeutic, Chinese medicine has the certain curative effect xerophthalmia except that the sweet tear of Huang, and DONGSHEN tear etc. are invalid substantially.The research that shows traditional Chinese medical science topical therapeutic xerophthalmia is also very limited, also is in the starting stage
Ophthalmology discovers that the tear film is made up of three layers of different separable film.These layers comprise: lipid, moisture content and mucus.Most of xerophthalmia patients are that lipid is destroyed.Liposome in the liposome artificial tears eye drop plays the effect (liposome is average 150 nanometers of trickle vesicle diameter that swim in aqueous phase) that discharges phospholipid, help to increase spontaneous lipid conformation within the eye, improve the quality of tear film, because the slow releasing function of liposome can be preserved moisture for a long time, and by slowly discharging vitamin A nutrition cornea epithelium.
Liposome artificial lacrimal eye drops can help to suffer from the xerophthalmia of dyslipidemias or evaporation, in fact is a sealant, seals the effect that spontaneous lipid also can produce migration, joins in the composition of tear film.
The product that has gone on the market at present has:
The artificial tears of U.S. Allergan company, main component: polyvinyl alcohol;
The U.S. is liked and the tear in health eye pharmaceutical factory is right, main component: hypromellose, sodium borate; Happy: sodium chloride, sodium borate, potassium chloride;
The artificial tears of Japan Santen Pharmaceutical Co. Ltd., main component: hyaluronate sodium;
The abundant gel of the promise of Switzerland Novartis, main component: contain vitamin A corneal protection gel;
U.S. Bausch ﹠ Lomb Inc only ceases gel, main component: 0.2% carbomer, 4% sorbitol.
The clean eye drops of profit of honest Fu Ruida pharmaceutical Co. Ltd, main component: vitamin B6, hyaluronic acid sodium, taurine;
Nanjing Li Xin Pharma Inc. replaces as if the eye drop artificial tears main component: contain thickening agent.Auspicious pearl (polyvinyl alcohol eye drop) preservative free artificial tears provides the eye table to moisten lastingly, is fit to prolonged application and alleviates symptoms such as eye dryness, foreign body sensation, asthenopia, single packing.
From these product main components is water, inorganic salt, thickening agent and water-soluble nutrient substance.The abundant gel of promise that has only Switzerland Novartis to produce contains fat-soluble A, and its composition is VitA cetylate 10mg (1000IU)/g, polyacrylic acid (Carbopol980) 3.5mg/g, salt cetrimonium bromide 0.1mg/g.Indication: promote corneal healing, the treatment xerophthalmia.Dosage: adult and child: one day 3-4 time, each one or decide on the degree of being in a bad way.Unless the interests of medication much larger than danger, are not advocated to use this product in gestation and nursing women.Untoward reaction: idol has of short duration burn feeling and eyelid adhesion and/or blurred vision, and anaphylaxis seldom takes place.
Artificial tears and the natural tears that goes on the market both at home and abroad at present more all lacks lipid as previously mentioned, because of lipid can not be water-soluble so can not be prepared into eye drop.
Tear by twinkling of eyelid and the wandering eye surface that is distributed in of the tear of tear, forms the tear film of being made up of rete malpighii, slurry layer and lipid layer (seeing accompanying drawing 1,2) in fissura palpebrae portion in conjunctival sac.Lipid layer is positioned at the outermost layer of tear film, and body temperature is liquid down, and mainly by the tarsal glands secretion, composition is compositions such as phospholipid (PL), triglyceride, free fatty and free cholesterol.Phosphatidylcholine (PC) wherein, PHOSPHATIDYL ETHANOLAMINE (PE) and sphingomyelins are main component.Main effect is the stability that prevents the evaporation of tear and strengthen the tear film.In addition, lipid layer can also provide the damage of twinkling and cause with minimizing in slick plane.Slick lipid layer still is good refracting media.Under the normal condition, the evaporation capacity of tear is about 0.15mL/min, if do not have lipid layer, then evaporates 0.85-1.7mL/min, can reach under the normal condition more than 10 times.Currently should avoid using the artificial tear of tradition, because of it only is the taking stopgap measures effect that the eye table adds water, but and should use and contain the artificial tear treating both the principal and secondary aspects of a disease that the treatment epithelium is done change or lachrymal gland pathological changes, be artificial tear of the 5th generation.The beginning of the nineties, just the someone advocated to add in the artificial tear nutrient such as vitamin B12 and A.Vitamin A is the nutritional labeling of needed by human, absorbs through intestinal mucosa in vivo to be converted into retinol, and retinol plays important effect to visual system.Vitamin A is participated in the metabolism of cornea directly, keeps the normal function of cornea.
The eye drop administration because the effect of ocular movement and nose tear system makes a large amount of drug loss, needs multiple dosing every day, and dosage is inaccurate, and the intraocular drug fluctuation of concentration is big; Suspension or ointment administration affect one's power of vision again and ocular movement.For overcoming above-mentioned shortcoming, adopt to add hydrophilic gel carbomer (carbomer) increase viscosity, delay the holdup time of medicine, increase absorption; But make blurred vision easily, influence eyelid movement; Or implant long lasting controlled-release administrating system, but the patient has foreign body sensation.Ideal dosing eyes system should be able to keep drug depot, discharges medicine for a long time; Can penetrate cornea effectively, arrive each agents area of ophthalmic; Can reduce the part and the whole body toxic and side effects of original medicine; Preparation is transparent, does not influence the normal physiological function of eye.
The present invention is through discovering, using low dosage (0.25mg/ml) vitamin A palmitate is safe and effective for preventing and treating xerophthalmia and eyestrain, there is not any untoward reaction, simultaneously vitamin A palmitate is made liposome artificial lacrimal eye drops, be particularly suitable for xerophthalmia and asthenopic treatment, and need not antiseptic.
Liposome of the present invention is as the dosing eyes system, and its composition material is a phosphide, cholesterol, and vitamin E (antioxidant), rather similar to the lipid layer of tear.Can promote medicine to biomembranous penetrance behind the liposomal encapsulated medicine, thus medicine external eye drip to stride the cornea transport efficacy higher; By selecting different preparation methoies, making the liposome particle diameter is between 100nm～500nm, and splashing into eye does not have foreign body sensation, does not influence the eyes normal physiological function.
Summary of the invention:
The invention provides the artificial tears of the liposomal encapsulated fat-soluble A of a kind of usefulness, both replenished the lipid among the artificial tears and also added nutrient.
Of the present invention consisting of:
Fat-soluble A, liposomal encapsulated material, vitamin E and artificial tears's hydrating fluid.
Wherein, fat-soluble A is vitamin A palmitate or vitamin A acetate.
Liposomal encapsulated material is granulesten and cholesterol.
Artificial tears's hydrating fluid consist of sodium bicarbonate, sodium chloride, glucose, potassium chloride, calcium chloride, water etc., also can add Mentholum, PVP, one or more of auxiliary elements such as HPMC as required in addition, artificial tears's hydrating fluid of the present invention is a prior art, can be by the preparation of prior art means.
Of the present invention consisting of: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.125-10.0g with vitamin A
Soybean phospholipid 4.45-17.8g
Cholesterol 0.55-2.2g
Vitamin E 0.025-0.1g
All the other are water
The composition of 1000ml artificial tears hydrating fluid:
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
All the other are water, Mentholum, and PVP, auxiliary elements such as HPMC, water, Mentholum, PVP, the addition of HPMC is to regulate according to the total amount of artificial tears's hydrating fluid, belongs to prior art.
Preferred group of the present invention becomes: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.2-1.0g with vitamin A
Soybean phospholipid 8-10g
Cholesterol 1-1.2g
Vitamin E 0.04-0.06g
All the other are water
Most preferred consisting of of the present invention: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.25-0.5g with vitamin A
Soybean phospholipid 8.90g
Cholesterol 1.10g
Vitamin E 0.05g
All the other are water
Most preferred composition example of the present invention is seen the embodiment of the invention.
The key technical indexes of the present invention is:
Contain 0.25mg-10mg among the principal agent concentration .:1ml.
This product contains vitamin A palmitate (C
36H
60O
2) or vitamin A acetate should be the 90.0-110.0% of labelled amount.
PH value: 5.0-7.0.
Liposomal encapsulated vitamin A palmitate or vitamin A acetate, envelop rate is 70～95%.
Liposome is made up of granulesten and cholesterol, and the mol ratio of granulesten and cholesterol is 7: 3.
Antioxidant is a vitamin E.
The liposome particle diameter is 50～500nm.
Peroxide value must not be crossed 15meq/L.
Osmotic pressure: should be 230-340mSoM.
Thickening agent is PVP (concentration is 0.002%)
Other indexs should meet the Chinese people two (version in 2005) appendix XIX E of state's pharmacopeia microcapsule, microsphere and Liposomal formulation guideline altogether; Appendix I J eye drop general rule.
The present invention's's " vitamin A liposome artificial lacrimal eye drops " preparation method can be following method:
1. take by weighing the vitamin A palmitate of recipe quantity or vitamin A acetate, soybean phospholipid, cholesterol, vitamin E, with chloroform or dehydrated alcohol or ether or petroleum ether dissolution.
With lipid soln on membrane evaporator, decompression is removed organic solvent and is got lipid film.
3. by prescription preparation artificial tears hydrating fluid, aseptic filtration is standby.
4. with solution 3 impouring immobilized artificial membranes, treat the complete aquation of immobilized artificial membrane after, with the high pressure homogenizer extruding, push repeatedly 10 times or prepare liposome with the ultrasonic cell disintegration crusher machine, granularity should be at 60-500nm.
5. under the sterile working, 0.4 milliliter of single dose packing promptly.
Of the present invention is a kind of artificial lacrimal eye drops; feature is with liposomal encapsulated with fat-soluble vitamin A; make it water-soluble; not only contain the vitamin A (being commonly called as the xerophthalmia vitamin) of protecting eyes; and contain in the natural tears indispensable lipid and eyes are also had good action as the E that supports one's family of antioxidant, achieve many things at one stroke.Single dose bag (0.4ml/ props up) does not contain antiseptic, antiseptic damage corneal epithelium when avoiding life-time service.
Feature of the present invention also is, uses low dosage vitamin A effect best, has no side effect, and in conjunction with having promoted curative effect, makes eyes more comfortable vitamin A and liposome, has synergism.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.25g with vitamin A
Soybean phospholipid 8.90g
Cholesterol 1.10g
Vitamin E 0.05g
1000ml
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
1000ml
PH value: 5.0～7.0
Preparation method is as follows:
1. take by weighing the vitamin A palmitate of recipe quantity or vitamin A acetate, soybean phospholipid, cholesterol, vitamin E, with chloroform or dehydrated alcohol or ether or petroleum ether dissolution.
With lipid soln on membrane evaporator, decompression is removed organic solvent and is got lipid film.
3. by prescription preparation hydrating fluid, aseptic filtration is standby.
4. with solution 3 impouring immobilized artificial membranes, treat the complete aquation of immobilized artificial membrane after, with the high pressure homogenizer extruding, push repeatedly 10 times or prepare liposome with the ultrasonic cell disintegration crusher machine, granularity should be at 60-500nm.
5. under the sterile working, 0.4 milliliter of single dose packing promptly.
Embodiment 2:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.5g with vitamin A
Soybean phospholipid 8.25g
Cholesterol 1.75g
Vitamin E 0.05g
1000ml
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
Mentholum 10mg
PVP 20mg
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 3:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 1.0g with vitamin A
Soybean phospholipid 7.52g
Cholesterol 2.48g
Vitamin E 0.05g
1000ml
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
HPMC 250mg
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 4:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.25g with vitamin A
Soybean phospholipid 8.90g
Cholesterol 1.10g
Vitamin E 0.05g
1000ml
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
HPMC 250mg
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 5:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.25g with vitamin A
Soybean phospholipid 8.90g
Cholesterol 1.10g
Vitamin E 0.05g
1000ml
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
Mentholum 10mg
PVP 20mg
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 6:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.125g with vitamin A
Soybean phospholipid 4.45g
Cholesterol 0.55g
Vitamin E 0.025g
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 7:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 10.0g with vitamin A
Soybean phospholipid 17.8g
Cholesterol 2.2g
Vitamin E 0.1g
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 8:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 0.2g with vitamin A
Soybean phospholipid 8g
Cholesterol 1g
Vitamin E 0.04g
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Embodiment 9:
Prescription: 1000ml fat-soluble A liposome
Vitamin A palmitate or vitamin A acetate (calculating) 1.0g with vitamin A
Soybean phospholipid 10g
Cholesterol 1.2g
Vitamin E 0.06g
The preparation of hydrating fluid: 1000ml
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
1000ml
PH value: 5.0～7.0
Preparation method is identical with embodiment 1.
Claims (7)
1. a vitamin A liposome artificial lacrimal eye drops is characterized in that, it consists of vitamin A palmitate or vitamin A acetate, liposomal encapsulated material, and vitamin E and artificial tears's hydrating fluid, wherein liposomal encapsulated material is granulesten and cholesterol; Artificial tears's hydrating fluid consist of sodium bicarbonate, sodium chloride, glucose, potassium chloride, calcium chloride, wherein consisting of of 1000ml fat-soluble A liposome:
Vitamin A palmitate or vitamin A acetate 0.125-10.0g
Soybean phospholipid 4.45-17.8g
Cholesterol 0.55-2.2g
Vitamin E 0.025-0.1g
All the other are water.
2. the eye drop of claim 1 is characterized in that, wherein consisting of of 1000ml fat-soluble A liposome:
Vitamin A palmitate or vitamin A acetate 0.2-1.0g
Soybean phospholipid 8-10g
Cholesterol 1-1.2g
Vitamin E 0.04-0.06g
All the other are water.
3. the eye drop of claim 1 is characterized in that, wherein, and consisting of of 1000ml fat-soluble A liposome wherein:
Vitamin A palmitate or vitamin A acetate 0.25-0.5g
Soybean phospholipid 8.90g
Cholesterol 1.10g
Vitamin E 0.05g
All the other are water.
4. the eye drop of claim 1 is characterized in that, wherein consisting of of 1000ml artificial tears hydrating fluid:
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g.
5. the eye drop of claim 1 is characterized in that, wherein consisting of of 1000ml artificial tears hydrating fluid:
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
Mentholum 10mg
PVP 20mg。
6. the eye drop of claim 1 is characterized in that, wherein consisting of of 1000ml artificial tears hydrating fluid:
Sodium bicarbonate 0.20g
Sodium chloride 9.00g
Glucose 1.00g
Potassium chloride 0.14g
Calcium chloride 0.42g
HPMC 250mg。
7. the eye drop of claim 1 is used for preventing and treating the application of xerophthalmia and asthenopic medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100838419A CN100393303C (en) | 2006-06-05 | 2006-06-05 | Vitamin A liposome artificial lacrimal eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100838419A CN100393303C (en) | 2006-06-05 | 2006-06-05 | Vitamin A liposome artificial lacrimal eye drops |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1850054A CN1850054A (en) | 2006-10-25 |
| CN100393303C true CN100393303C (en) | 2008-06-11 |
Family
ID=37131566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100838419A Active CN100393303C (en) | 2006-06-05 | 2006-06-05 | Vitamin A liposome artificial lacrimal eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100393303C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4419145A4 (en) * | 2021-10-19 | 2025-03-12 | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi | OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA, KERATOCONJUNCTIVITIS SCIENCE AND COMPUTER VISION SYNDROME |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101884416A (en) * | 2010-07-08 | 2010-11-17 | 东北农业大学 | A method of embedding vitamin A acetate |
| CN105394774A (en) * | 2015-11-22 | 2016-03-16 | 威海百合生物技术股份有限公司 | Method for improving solubility of vitamin A acetic ester |
| CN110559261A (en) * | 2018-06-06 | 2019-12-13 | 常州药物研究所有限公司 | Liposome microemulsion containing nano cross-linked hyaluronic acid and preparation method and application thereof |
| HRP20220180T1 (en) * | 2018-12-28 | 2022-04-29 | Dr. Rolf Lambert Pharma-Consulting Gmbh | Liposomial eye drops solution and uses thereof for the treatment of dry eye syndrome |
| WO2021107033A1 (en) * | 2019-11-29 | 2021-06-03 | 千寿製薬株式会社 | Pharmaceutical composition |
| CN111467349B (en) * | 2020-05-14 | 2021-06-01 | 华熙生物科技股份有限公司 | Artificial tear and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170364A (en) * | 1994-12-19 | 1998-01-14 | 大正制药株式会社 | Liposome eye drops |
| CN1410055A (en) * | 2002-06-06 | 2003-04-16 | 上海家化联合股份有限公司 | Vitamin A liposome and its preparation method |
| CN1456167A (en) * | 2003-03-31 | 2003-11-19 | 凌沛学 | Artificial tear containing phosphatide and preparing method thereof |
-
2006
- 2006-06-05 CN CNB2006100838419A patent/CN100393303C/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170364A (en) * | 1994-12-19 | 1998-01-14 | 大正制药株式会社 | Liposome eye drops |
| CN1410055A (en) * | 2002-06-06 | 2003-04-16 | 上海家化联合股份有限公司 | Vitamin A liposome and its preparation method |
| CN1456167A (en) * | 2003-03-31 | 2003-11-19 | 凌沛学 | Artificial tear containing phosphatide and preparing method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4419145A4 (en) * | 2021-10-19 | 2025-03-12 | VSY Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi | OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA, KERATOCONJUNCTIVITIS SCIENCE AND COMPUTER VISION SYNDROME |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1850054A (en) | 2006-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7324566B2 (en) | Aqueous ophthalmic composition | |
| CA2667072C (en) | Gel useful for the delivery of ophthalmic drugs | |
| US9119827B2 (en) | Ophthalmic composition | |
| CN101028240B (en) | Ophthalmic microemulsion/submicroemulsion in-situ gel preparation and preparation method thereof | |
| CN102078284B (en) | Gatifloxacin-containing gel for eyes and preparation method thereof | |
| TWI535462B (en) | Ophthalmic pharmaceutical compositions and methods of making and using same | |
| CN106511322A (en) | Compositions comprising mixtures of semifluorinated alkanes | |
| CN101095695A (en) | Liposome artificial tear eye drops | |
| CN101401791A (en) | Timolol liposome and preparation method thereof | |
| CN109260146A (en) | Ophthalmic solution sodium in situ forming eye type gel eyedrop and preparation method | |
| CN100393303C (en) | Vitamin A liposome artificial lacrimal eye drops | |
| CN110090294A (en) | Ophthalmic composition with improved dry-run protection and reservation | |
| CN113577024B (en) | Ophthalmic composition, preparation method and application thereof | |
| JP4836401B2 (en) | Ophthalmic composition | |
| CN102100665B (en) | Eye drops containing vitamin E derivatives and preparation method thereof | |
| JP2025160514A (en) | Liquid preparations containing brimonidine | |
| CN101642426B (en) | Baicalin adhesion type nanometer eye drops and preparation method thereof | |
| Aiache et al. | The formulation of drug for ocular administration | |
| CN1883469B (en) | An ocular microemulsion containing Vitamin A and Vitamin E and preparation method thereof | |
| CN111494305A (en) | Lutein liposome ophthalmic temperature-sensitive in-situ gel preparation and preparation method thereof | |
| CN102198087B (en) | Preservative-free ophthalmic in-situ gelling agent and preparation method thereof | |
| CN101491532A (en) | Erigeron breviscapus eye-preparation and preparation method thereof | |
| CN110559261A (en) | Liposome microemulsion containing nano cross-linked hyaluronic acid and preparation method and application thereof | |
| CN100562340C (en) | Micro-emulsion type artificial tear | |
| CN102018656A (en) | Eye gel containing latanoprost used as effective component and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SAIKE PHARMACY CO., LTD. Free format text: FORMER OWNER: ZHUHAI LIBO PHARMACEUTICAL SCI. + TECH CO., LTD. Effective date: 20080912 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: Beijing City, Chaoyang District Jinsong three District No. 302 Huateng building room 1101 Patentee after: Saike Pharmaceutical Co., Ltd., Beijing Address before: A-908-909, Tsinghua Science and Technology Park, 101 University Road, Tang Wan Road, Guangdong, Zhuhai Patentee before: Libo Medicine Scinece & Tech. Co., Ltd., Zhuhai |
|
| C56 | Change in the name or address of the patentee |
Owner name: HUARUN SAIKE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: SAIKE PHARMACEUTICAL CO., LTD., BEIJING |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 100021 Beijing city Chaoyang District Jinsong three District No. 302 Huateng building room 1101 Patentee after: China Resources Saike Pharmaceutical Co., Ltd. Address before: 100021 Beijing city Chaoyang District Jinsong three District No. 302 Huateng building room 1101 Patentee before: Saike Pharmaceutical Co., Ltd., Beijing |